Novo Nordisk is pressing ahead with obesity and cardiometabolic drug development, including CagriSema regulatory submissions and a partnership with Prothena on Coramitug, while also running a DKK 15b share buyback that has added to its treasury share position since February 2026. Growing competition from Eli Lilly and Viking Therapeutics, together with fresh US scrutiny of GLP-1 linked supplement use, highlights both the strength of Novo Nordisk's core obesity franchise and the regulatory and execution pressures around how these medicines are used in real world care. The focus now turns to how Novo Nordisk's investment narrative could be shaped by GLP-1 momentum under tighter US supplement oversight.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.